Rigel Pharmaceuticals Inc
RIGL35.110USD
+0.890+2.60%
Cierre 09/18, 16:00（ET）Cotizaciones retrasadas 15 min
629.77MCap. mercado
6.44P/E TTM
Más Datos de Rigel Pharmaceuticals Inc Compañía
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
Información de la empresa
Símbolo de cotizaciónRIGL
Nombre de la empresaRigel Pharmaceuticals Inc
Fecha de salida a bolsaNov 29, 2000
Director ejecutivoMr. Raul R. Rodriguez
Número de empleados162
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 29
Dirección- -
Ciudad- -
Bolsa de valoresNASDAQ Global Select Consolidated
País- -
Código postal- -
Teléfono- -
Sitio Web- -
Símbolo de cotizaciónRIGL
Fecha de salida a bolsaNov 29, 2000
Director ejecutivoMr. Raul R. Rodriguez
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Raul R. Rodriguez
Mr. Raul R. Rodriguez
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
239.45K
-3.76%
Mr. Dean L. Schorno, CPA
Mr. Dean L. Schorno, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
57.23K
-6.18%
Mr. David A. Santos
Mr. David A. Santos
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
51.70K
-7.05%
Dr. Lisa Rojkjaer, M.D.
Dr. Lisa Rojkjaer, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
19.72K
--
Dr. Walter H. Moos, Ph.D.
Dr. Walter H. Moos, Ph.D.
Independent Director
Independent Director
12.72K
+24.46%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
12.50K
+25.00%
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
9.38K
+36.36%
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alison L. Hannah, M.D.
Dr. Alison L. Hannah, M.D.
Independent Director
Independent Director
--
--
Mr. Raymond J. Furey
Mr. Raymond J. Furey
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Raul R. Rodriguez
Mr. Raul R. Rodriguez
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
239.45K
-3.76%
Mr. Dean L. Schorno, CPA
Mr. Dean L. Schorno, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
57.23K
-6.18%
Mr. David A. Santos
Mr. David A. Santos
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
51.70K
-7.05%
Dr. Lisa Rojkjaer, M.D.
Dr. Lisa Rojkjaer, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
19.72K
--
Dr. Walter H. Moos, Ph.D.
Dr. Walter H. Moos, Ph.D.
Independent Director
Independent Director
12.72K
+24.46%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
12.50K
+25.00%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 16 de ago
Actualizado: sáb., 16 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Armistice Capital LLC
8.92%
Morgan Stanley & Co. LLC
8.25%
BlackRock Institutional Trust Company, N.A.
7.85%
The Vanguard Group, Inc.
5.87%
Soleus Capital Management, L.P.
3.67%
Otro
65.45%
Accionistas
Accionistas
Proporción
Armistice Capital LLC
8.92%
Morgan Stanley & Co. LLC
8.25%
BlackRock Institutional Trust Company, N.A.
7.85%
The Vanguard Group, Inc.
5.87%
Soleus Capital Management, L.P.
3.67%
Otro
65.45%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
29.38%
Investment Advisor/Hedge Fund
23.07%
Hedge Fund
16.28%
Research Firm
10.35%
Individual Investor
2.65%
Pension Fund
0.76%
Bank and Trust
0.14%
Insurance Company
0.04%
Otro
17.33%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
290
14.23M
79.32%
-22.43K
2025Q1
295
14.90M
83.36%
+888.64K
2024Q4
281
12.77M
72.51%
-849.60K
2024Q3
291
12.41M
70.53%
-421.54K
2024Q2
303
10.88M
61.98%
-2.99M
2024Q1
319
11.57M
65.99%
-3.84M
2023Q4
326
11.03M
63.24%
-4.70M
2023Q3
343
11.50M
66.01%
-5.45M
2023Q2
356
11.96M
68.88%
-4.98M
2023Q1
359
12.15M
69.98%
-5.32M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Armistice Capital LLC
1.52M
8.48%
+364.00K
+31.60%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.48M
8.28%
-54.14K
-3.53%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.47M
8.23%
-33.13K
-2.20%
Mar 31, 2025
The Vanguard Group, Inc.
1.03M
5.75%
+15.14K
+1.49%
Mar 31, 2025
Soleus Capital Management, L.P.
1.13M
6.33%
--
--
Mar 31, 2025
Acadian Asset Management LLC
565.04K
3.16%
+188.68K
+50.13%
Mar 31, 2025
State Street Global Advisors (US)
637.03K
3.56%
+256.52K
+67.41%
Mar 31, 2025
Capitolis Liquid Global Markets LLC
693.10K
3.88%
+693.10K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
411.17K
2.3%
+9.12K
+2.27%
Mar 31, 2025
Marshall Wace LLP
211.75K
1.18%
+211.75K
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de sep
Actualizado: sáb., 6 de sep
Nombre
Proporción
Invesco Nasdaq Biotechnology ETF
0.07%
Franklin US Small Cap Multifactor Index ETF
0.05%
Innovator US Small Cap Managed Floor ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Russell 2000 Dynamic Multifactor ETF
0.04%
ProShares Hedge Replication ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
Avantis Responsible US Equity ETF
0.01%
Pacer US Small Cap Cash Cows ETF
0%
Ver más
Invesco Nasdaq Biotechnology ETF
Proporción0.07%
Franklin US Small Cap Multifactor Index ETF
Proporción0.05%
Innovator US Small Cap Managed Floor ETF
Proporción0.04%
ProShares Ultra Nasdaq Biotechnology
Proporción0.04%
Invesco Russell 2000 Dynamic Multifactor ETF
Proporción0.04%
ProShares Hedge Replication ETF
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%
Avantis Responsible US Equity ETF
Proporción0.01%
Pacer US Small Cap Cash Cows ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Fecha
Tipo
Relación
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
